Latham Leads Kailera's $625M IPO In Obesity Drug Push
Obesity biotech Kailera Therapeutics made its public debut Friday, raising $625 million in an upsized initial public offering that represents one of the largest biotech IPOs in recent years....To view the full article, register now.
Already a subscriber? Click here to view full article